Myelofibrosis (MF) is a myeloproliferative neoplasm (MPN) with a poor prognosis, and allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only treatment with curative potential. Ruxolitinib, a JAK1/2 inhibitor, has shown promising results in improving patients' symptoms, overall survival, and quality of life, and can be used as a bridging therapy to HSCT that increases the proportion of transplantable patients. However, the effect of this and similar drugs on HSCT outcomes is unknown, and the reports on their efficacy and safety in the peri-transplantation period vary widely in the published literature. This paper reviews clinical data related to the use of JAK inhibitors in the peri-implantation phase of hematopoietic stem cell transplantation for primary myelofibrosis and discusses their efficacy and safety.
Keyphrases
- poor prognosis
- end stage renal disease
- allogeneic hematopoietic stem cell transplantation
- ejection fraction
- chronic kidney disease
- acute myeloid leukemia
- prognostic factors
- newly diagnosed
- long non coding rna
- systematic review
- peritoneal dialysis
- stem cells
- type diabetes
- acute lymphoblastic leukemia
- randomized controlled trial
- risk assessment
- cell therapy
- insulin resistance
- deep learning
- mesenchymal stem cells
- adverse drug
- skeletal muscle
- sleep quality
- meta analyses